AZD‐4547 is a highly selective FGFR inhibitor; a patient‐derived xenograft model of FGFR1‐amplified lung cancer was highly sensitive to AZD4547 as single agent.24 Our experimental results notably indicate that AZD‐4547 combined with erlotinib significantly restored the sensitivity of HCC827‐TR cells to the EGFR‐TKI both in low‐ and high‐concentration groups. This evidence concerns the gene EGFR and lung carcinoma.